Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck neurology, cardiovascular news

MRK agreed to set aside $4.9 billion to settle a majority of product liability claims filed in U.S. state and federal courts related to pain drug Vioxx rofecoxib. MRK estimated between

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE